Marcus Borenäs | Ruth Palmer Labhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/marcus-borenas/Marcus BorenäsHugo Blox Builder (https://hugoblox.com)en-ushttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/marcus-borenas/avatar_huf6fb39c49cdaf4bbe07d6d85dfa48a2e_126642_270x270_fill_q75_lanczos_center.jpegMarcus Borenäshttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/marcus-borenas/RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/ruvbl1_ruvbl2_neuroblastoma/Fri, 17 Apr 2026 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/ruvbl1_ruvbl2_neuroblastoma/Spatial transcriptomics exploration of the primary neuroblastoma microenvironment in archived FFPE samples unveils novel paracrine interactionshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/spatial_transcriptomics_neuroblastoma/Wed, 01 Oct 2025 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/spatial_transcriptomics_neuroblastoma/Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell growthhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/slc3a2/Mon, 10 Jun 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/slc3a2/ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibitionhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/Tue, 02 Jan 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathwayhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/igf1r/Fri, 25 Aug 2023 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/igf1r/<h1 id="heading"></h1> <div class="alert alert-note"> <div> <p>#Click the <em>Cite</em> button above to demo the feature to enable visitors to import publication metadata into their reference management software.</p> <h1 id="heading"></h1> </div> </div> <h1 id="heading-1"></h1> <div class="alert alert-note"> <div> <p>#Create your slides in Markdown - click the <em>Slides</em> button to check out the example.</p> <h1 id="heading"></h1> </div> </div> <p>#Add the publication&rsquo;s <strong>full text</strong> or <strong>supplementary notes</strong> here. You can use rich formatting such as including <a href="https://docs.hugoblox.com/content/writing-markdown-latex/" target="_blank" rel="noopener">code, math, and images</a>.</p>ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutationhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/Mon, 01 Feb 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGalpha) in neuroblastoma patient samples with chromosome arm 2p rearrangementshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_patient_samples/Wed, 01 Jan 2020 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_patient_samples/Repotrectinib (TPX-0005) effectively reduces growth of ALK-driven neuroblastoma cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/repotrectinib/Wed, 18 Dec 2019 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/repotrectinib/Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alectinib_neuroblastoma/Tue, 01 Jan 2019 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alectinib_neuroblastoma/